{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T02:29:16Z","timestamp":1775788156353,"version":"3.50.1"},"publisher-location":"New York, NY","reference-count":16,"publisher":"Springer US","isbn-type":[{"value":"9781071645413","type":"print"},{"value":"9781071645420","type":"electronic"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/978-1-0716-4542-0_16","type":"book-chapter","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T10:18:55Z","timestamp":1745403535000},"page":"207-221","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Dendritic Cell Cancer Vaccines: Clinical Production for Cancer Immunotherapy"],"prefix":"10.1007","author":[{"given":"Hoyoung M.","family":"Maeng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Purevdorj B.","family":"Olkhanud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Black","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve L.","family":"Highfill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David F.","family":"Stroncek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay A.","family":"Berzofsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"key":"16_CR1","doi-asserted-by":"publisher","first-page":"e2249917","DOI":"10.1002\/eji.202249917","volume":"53","author":"L Heger","year":"2022","unstructured":"Heger L, Dudziak D, Amon L et al (2022) Guidelines for DC preparation and flow cytometric analysis of human lymphohematopoietic tissues. Eur J Immunol 53:e2249917. https:\/\/doi.org\/10.1002\/eji.202249917","journal-title":"Eur J Immunol"},{"key":"16_CR2","first-page":"5534","volume":"57","author":"R Mortarini","year":"1997","unstructured":"Mortarini R, Anichini A, Di Nicola M et al (1997) Autologous dendritic cells derived from CD34+ progenitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of melan-A\/Mart-1(27-35)-specific CTLs from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursors. Cancer Res 57:5534\u20135541","journal-title":"Cancer Res"},{"key":"16_CR3","doi-asserted-by":"publisher","unstructured":"Maeng HM, Berzofsky JA (2019) Strategies for developing and optimizing cancer vaccines. F1000Res 8. https:\/\/doi.org\/10.12688\/f1000research.18693.1","DOI":"10.12688\/f1000research.18693.1"},{"key":"16_CR4","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1197459","volume":"5","author":"LV Wood","year":"2016","unstructured":"Wood LV, Fojo A, Roberson BD et al (2016) TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with stage D0 prostate cancer. Oncolmmunology 5:e1197459. https:\/\/doi.org\/10.1080\/2162402X.2016.1197459","journal-title":"Oncolmmunology"},{"key":"16_CR5","doi-asserted-by":"publisher","unstructured":"Maeng HM, Moore BN, Bagheri H et al (2021) Phase I clinical trial of an autologous dendritic cell vaccine against HER2 shows safety and preliminary clinical efficacy. Front Oncol 11. https:\/\/doi.org\/10.3389\/fonc.2021.789078","DOI":"10.3389\/fonc.2021.789078"},{"key":"16_CR6","first-page":"1099","volume":"55","author":"H Bernhard","year":"1995","unstructured":"Bernhard H, Disis ML, Heimfeld S et al (1995) Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood. Cancer Res 55:1099\u20131104","journal-title":"Cancer Res"},{"key":"16_CR7","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1158\/0008-5472.CAN-12-2583","volume":"73","author":"J Tel","year":"2013","unstructured":"Tel J, Aarntzen EH, Baba T et al (2013) Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res 73:1063\u20131075. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-2583","journal-title":"Cancer Res"},{"key":"16_CR8","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1002\/1521-4141(200012)30:12<3591::AID-IMMU3591>3.0.CO;2-J","volume":"30","author":"T Sparwasser","year":"2000","unstructured":"Sparwasser T, Vabulas RM, Villmow B et al (2000) Bacterial CpG-DNA activates dendritic cells in vivo: T helper cell-independent cytotoxic T cell responses to soluble proteins. Eur J Immunol 30:3591\u20133597","journal-title":"Eur J Immunol"},{"key":"16_CR9","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/nri1592","volume":"5","author":"J Banchereau","year":"2005","unstructured":"Banchereau J, Palucka AK (2005) Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 5:296\u2013306","journal-title":"Nat Rev Immunol"},{"issue":"27","key":"16_CR10","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/00002371-200405000-00003","volume":"1997","author":"L Schumacher","year":"2004","unstructured":"Schumacher L, Ribas A, Dissette VB et al (2004) Human dendritic cell maturation by adenovirus transduction enhances tumor antigen-specific T-cell responses. J Immunother 1997(27):191\u2013200","journal-title":"J Immunother"},{"key":"16_CR11","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/cr.2016.157","volume":"27","author":"RL Sabado","year":"2017","unstructured":"Sabado RL, Balan S, Bhardwaj N (2017) Dendritic cell-based immunotherapy. Cell Res 27:74\u201395. https:\/\/doi.org\/10.1038\/cr.2016.157","journal-title":"Cell Res"},{"key":"16_CR12","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jim.2005.05.010","volume":"302","author":"M Dauer","year":"2005","unstructured":"Dauer M, Schad K, Herten J et al (2005) FastDC derived from human monocytes within 48 h effectively prime tumor antigen-specific cytotoxic T cells. J Immunol Methods 302:145\u2013155. https:\/\/doi.org\/10.1016\/j.jim.2005.05.010","journal-title":"J Immunol Methods"},{"key":"16_CR13","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/j.1365-2249.2005.02699.x","volume":"139","author":"G Ramadan","year":"2005","unstructured":"Ramadan G, Davies B, Kurup VP, Keever-Taylor CA (2005) Generation of Th1 T cell responses directed to a HLA Class II restricted epitope from the Aspergillus f16 allergen. Clin Exp Immunol 139:257\u2013267. https:\/\/doi.org\/10.1111\/j.1365-2249.2005.02699.x","journal-title":"Clin Exp Immunol"},{"key":"16_CR14","unstructured":"FDA U. Current good manufacture practices guidances. https:\/\/www.fda.gov\/animal-veterinary\/guidance-industry\/current-good-manufacture-practices-guidances"},{"key":"16_CR15","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.jcyt.2018.03.001","volume":"20","author":"P Jin","year":"2018","unstructured":"Jin P, Chen W, Ren J et al (2018) Plasma from some cancer patients inhibits adenoviral Ad5f35 vector transduction of dendritic cells. Cytotherapy 20:728\u2013739. https:\/\/doi.org\/10.1016\/j.jcyt.2018.03.001","journal-title":"Cytotherapy"},{"key":"16_CR16","doi-asserted-by":"publisher","first-page":"A364","DOI":"10.1136\/jitc-2020-SITC2020.0610","volume":"8","author":"O Reddy","year":"2020","unstructured":"Reddy O, Panch S, Pham C et al (2020) 610\u00a0Technical challenges in monocyte-derived dendritic cell vaccine manufacturing; a QI project. J Immunother Cancer 8:A364\u2013A366. https:\/\/doi.org\/10.1136\/jitc-2020-SITC2020.0610","journal-title":"J Immunother Cancer"}],"container-title":["Methods in Molecular Biology","Cancer Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-4542-0_16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T10:18:58Z","timestamp":1745403538000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-4542-0_16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9781071645413","9781071645420"],"references-count":16,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-4542-0_16","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"24 April 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}